ArticleBio-protocol2026
One-Step Affinity Purification of MarathonRT Reverse Transcriptase for RNA Sequencing Applications.
Article in Bio-protocol, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Production of MarathonRT and its comparison with commercial reverse transcriptases for tRNA sequencing library preparation.RNA biology · 2026Article
- Editorial: Technologies for RNA Detection.Bio-protocol · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transfer RNAs (tRNAs) are important regulators of translation and cellular function. Several high-throughput sequencing methods have been developed to quantitatively analyze tRNA isoacceptors in cells. However, the strong secondary structures and extensive post-transcriptional modification of most tRNA molecules present significant challenges for many reverse transcriptases, negatively impacting sequencing library preparation and causing quantification biases. Currently, the field utilizes processive next-generation reverse transcriptases (ngRTs), such as Induro (New England Biolabs) and UltraMarathonRT (RNAConnect), to address these issues. Despite being used in multiple protocols, these commercial products face little competition and remain costly. However, non-commercial alternatives, such as the original MarathonRT (MRT), are available from gene repositories. MRT is a next-generation reverse transcriptase derived from the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.